Trial Profile
A Phase I Study of Recombinant hGM-CSF Herpes Simplex Virus
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Sep 2016
Price :
$35
*
At a glance
- Drugs OrienX 010 (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- 31 Aug 2016 Status changed from recruiting to completed.
- 28 Sep 2013 New trial record